DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. lowered its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 22.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,565 shares of the medical device company's stock after selling 3,594 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in DexCom were worth $858,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC acquired a new position in shares of DexCom during the fourth quarter worth about $5,812,000. SBI Securities Co. Ltd. acquired a new position in shares of DexCom during the fourth quarter worth about $49,000. Farther Finance Advisors LLC lifted its stake in shares of DexCom by 29.3% during the first quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company's stock worth $209,000 after purchasing an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its stake in shares of DexCom by 34.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company's stock worth $357,000 after purchasing an additional 1,333 shares in the last quarter. Finally, Sanctuary Advisors LLC lifted its stake in shares of DexCom by 21.7% during the fourth quarter. Sanctuary Advisors LLC now owns 18,061 shares of the medical device company's stock worth $1,405,000 after purchasing an additional 3,226 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent research reports. Citigroup restated a "buy" rating and set a $102.00 price objective (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Piper Sandler reduced their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Barclays boosted their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Mizuho initiated coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Finally, The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $41,400.00. Following the completion of the transaction, the executive vice president now directly owns 95,102 shares of the company's stock, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 25,724 shares of company stock worth $2,157,034 over the last quarter. 0.32% of the stock is owned by corporate insiders.

DexCom Trading Down 3.3%

Shares of NASDAQ DXCM opened at $84.68 on Thursday. The stock's 50 day moving average price is $81.02 and its two-hundred day moving average price is $79.50. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.19. The stock has a market capitalization of $33.20 billion, a P/E ratio of 63.19, a PEG ratio of 1.87 and a beta of 1.46. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the company earned $0.32 EPS. The company's quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.